The Motley Fool
13 Mar 2026, 13:09 UTC · 27w ago
Verdict
Headline leans bullish. We score SNDX +1.00 across four claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish
Syndax Pharmaceuticals' total revenue surged to $172.4 million in 2025, up sharply from $23.7 million the prior year, driven by two approved therapies.
So whatA roughly seven-fold year-over-year revenue increase signals a fundamental transition from a speculative clinical-stage biotech to a commercial-stage company, justifying significant valuation re-rating.
More positive than 99% of claims this week
Revuforj, Syndax's first-in-class menin inhibitor, generated $44.2 million in Q4 net revenue (up 38% sequentially) and $124.8 million for full-year 2025.
Continue reading
5 related stories
More positive than 98% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
More positive than 96% of claims this week
Niktimvo, developed with Incyte, delivered $151.6 million in full-year net sales across the collaboration in 2025.
More positive than 84% of claims this week
Sphera Funds Management Ltd. bought 374,847 additional shares of Syndax Pharmaceuticals, bringing its total position to 762,563 shares.
So whatA notable hedge fund doubling down on its position signals positive insider conviction, though institutional 13F filings are backward-looking and typically have a moderate market impact.
More positive than 57% of claims this week
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
2d ago
−26.6%
Price is moving against the score
$17.62 vs $23.99 close before publication (Mar 12) · not market-adjusted
SNDX chart →
